View Older Stories View More Recent Stories

Dec 28, 2022 06:45AM U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
Dec 21, 2022 06:46AM Pfizer (PFE) Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
Dec 21, 2022 06:45AM Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
Dec 20, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts
Dec 10, 2022 01:00PM Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
Dec 9, 2022 11:15AM Pfizer Declares First-Quarter 2023 Dividend
Dec 9, 2022 06:47AM BioNTech SE (BNTX), Pfizer (PFE) Granted FDA Fast Track Designation for Single-Dose mRNA-Based COVID Vaccine
Dec 9, 2022 06:45AM Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
Dec 8, 2022 10:43AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Dec 8, 2022 10:40AM Pfizer (PFE) and BioNTech (BNTX) Receive U.S. FDA EUA for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Dec 8, 2022 10:39AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Dec 7, 2022 06:45AM U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
Dec 6, 2022 06:56AM Pfizer (PFE), Clear Creek Bio Announce Collaboration on SARS-CoV-2 Papain-Like Protease Research
Dec 6, 2022 06:45AM Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
Dec 1, 2022 10:00AM Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
Dec 1, 2022 08:05AM Roivant Sciences (ROIV) and Pfizer (PFE) Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Dec 1, 2022 08:00AM Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Dec 1, 2022 08:00AM Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Dec 1, 2022 01:00AM Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
Nov 28, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Nov 18, 2022 06:46AM BioNTech SE (BNTX) and Pfizer (PFE) Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster
Nov 18, 2022 06:45AM Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
Nov 17, 2022 05:53AM BioNTech SE (BNTX) and Pfizer (PFE) Advance Next-Generation COVID-19 Vaccine Strategy
Nov 16, 2022 06:30PM Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Nov 11, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Nov 10, 2022 09:45AM Pfizer (PFE) and BioNTech (BNTX) Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in EU
Nov 10, 2022 09:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
Nov 4, 2022 06:50AM Pfizer (PFE) and BioNTech (BNTX) Report Strong Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster
Nov 4, 2022 06:48AM Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Nov 4, 2022 06:47AM Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Nov 3, 2022 04:41PM General Mills, Audi, Pfizer Pausing Twitter Ads - DJ
Nov 3, 2022 09:10AM Pfizer's (PFE) Elranatamab Granted FDA Breakthrough Therapy Designation
Nov 3, 2022 09:10AM Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
Nov 2, 2022 12:45PM Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
Nov 1, 2022 06:37AM Pfizer (PFE) Reports Positive Top-Line Data of Phase 3 Trial for Respiratory Syncytial Virus (RSV) Vaccine Candidate
Nov 1, 2022 06:30AM Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Oct 24, 2022 07:02AM Zentalis Pharmaceuticals (ZNTL) Announces First ZN-c3 Clinical Development Collaboration with Pfizer (PFE)
Oct 19, 2022 11:46AM Pfizer (PFE) and BioNTech (BNTX) Receive Positive CHMP Opinion for COMIRNATY in Children 6 Months to less than 5 Years in the European Union
Oct 19, 2022 11:45AM Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
Oct 18, 2022 12:00PM Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022
Oct 13, 2022 06:47AM BioNTech SE (BNTX) and Pfizer (PFE) Report Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster
Oct 13, 2022 06:45AM Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Oct 13, 2022 06:45AM Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Oct 12, 2022 10:30AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Oct 12, 2022 10:16AM Pfizer (PFE), BioNTech (BNTX) Confirm U.S. FDA EUA for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Oct 12, 2022 10:16AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
Oct 5, 2022 09:03AM Pfizer (PFE) Completes Acquisition of Global Blood Therapeutics (GBT)
Oct 5, 2022 09:02AM Pfizer Completes Acquisition of Global Blood Therapeutics 
Oct 4, 2022 07:02AM Voyager Therapeutics (VYGR) Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Oct 3, 2022 01:01PM Pfizer (PFE) Completes Acquisition of Biohaven Pharmaceuticals
View More Recent Stories View Older Stories